2017-03-24,Lifshitz & Miller LLP Announces Investigation Of Argos Therapeutics, Inc., Avid Technology, Inc., HMS Holdings Corp., Invuity, Inc., SITO Mobile, Ltd., Trevena, Inc., USANA Health Sciences, Inc. And VAALCO Energy, Inc.
2017-03-22,Regenxbio Leads Biotech Movers Ahead of Market's Open
2017-03-21,First Week Of TRVN May 19th Options Trading
2017-03-17,2 Questions From the Biotech Mailbag
2017-03-15,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Trevena, Inc. (TRVN)
2017-03-15,TREVENA (TRVN) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of Trevena, Inc.; Investors Encouraged To Contact Firm
2017-03-15,INVESTOR ALERT: Investigation Of Trevena Announced By Holzer & Holzer, LLC
2017-03-14,Trevena To Present At The Oppenheimer 27th Annual Healthcare Conference
2017-03-10,Trevena To Present At The 2017 Barclays Global Healthcare Conference
2017-03-08,Trevena Reports Full Year 2016 Earnings
2017-03-02,Trevena To Host Conference Call On March 8th To Discuss Full Year 2016 Financial Results
2017-02-24,Why Cara Therapeutics Is Up, Trevena Down
2017-02-23,Will Insiders Be Tempted To Buy More TRVN At The New 52-Week Low?
2017-02-22,First Week of April 21st Options Trading For Trevena
2017-02-22,Argos Plummets 72%, Leads Biotech Movers
2017-02-21,Trevena Enters Oversold Territory
2017-02-21,Sarepta Leads Biotech Movers on Voucher Deal News
2017-02-21,Trevena Makes Case for Better Post-Surgical Opioid with New Study Data
2017-02-21,What You Should Know About Trevena's New Painkiller
2017-02-21,Trevena Announces Positive Top-line Results From Two Phase 3 Pivotal Efficacy Studies Of Intravenous Oliceridine In Moderate-to-Severe Acute Pain
2017-02-16,Notable Thursday Option Activity: TRVN, MIDD, ANET
2017-02-02,Market Is Leaving a Sour Taste
2017-01-09,When Will the Market Take a Dive?
2017-01-04,Trevena Completes Enrollment Of Phase 3 APOLLO Pivotal Efficacy Trials Of Oliceridine For Moderate-to-Severe Acute Pain
2016-12-20,First Week of TRVN February 2017 Options Trading
2016-12-02,Get Addicted to Trevena
2016-11-22,First Week of January 2017 Options Trading For Trevena (TRVN)
2016-11-18,No to Closed-End Muni Bond Funds; Cara on a Run: Best of Kass
2016-11-11,TRVN: Insiders vs. Shorts
2016-11-10,Interesting TRVN Call Options For November 18th
2016-11-03,Trevena Reports Third Quarter 2016 Financial Results And Provides Corporate Update
2016-10-19,Commit To Purchase Trevena At $5, Earn 24.5% Annualized Using Options
2016-10-17,Trevena To Webcast Thought Leader Symposium On Acute Pain Management And Present At The 2016 Annual Meeting Of The American Society Of Anesthesiologists
2016-10-06,Trevena Becomes Oversold (TRVN)
2016-08-10,Trevena To Present At The 2016 Wedbush Pacgrow Healthcare Conference
2016-08-05,Company Profile For Trevena, Inc.
2016-08-04,Trevena Reports Second Quarter 2016 Financial Results And Provides Corporate Update
2016-07-19,Commit To Buy Trevena At $5, Earn 16.7% Annualized Using Options
2016-06-20,Ratings Changes Today
2016-06-16,Trevena To Present At The JMP Life Sciences Conference
2016-06-08,Trevena, Inc. Announces First Patients Enrolled In The APOLLO-1 And APOLLO-2 Phase 3 Pivotal Efficacy Studies Of Oliceridine In Acute Pain
2016-06-01,Trevena To Present At The Jefferies 2016 Healthcare Conference
2016-05-16,Trevena is Now Oversold (TRVN)
2016-05-16,Trevena Reports TRV027 Did Not Achieve Primary Or Secondary Endpoints In BLAST-AHF Phase 2b Trial In Acute Heart Failure
2016-05-13,Ratings Changes Today
2016-05-11,Trevena Announces Presentations At The 35th Annual Scientific Meeting Of The American Pain Society
2016-05-05,Trevena Reports First Quarter 2016 Financial Results And Provides Corporate Update
2016-05-02,Trevena Announces Successful End-of-Phase 2 Meeting With FDA And Outlines Phase 3 Program For Oliceridine
2016-04-25,Noteworthy Monday Option Activity: TRVN, BLMN, CAVM
2016-04-20,First Week of December 16th Options Trading For Trevena (TRVN)
2016-04-07,Trevena To Present At The Needham & Company 15th Annual Healthcare Conference
2016-03-31,Trevena Announces Presentations At The 41st Annual Regional Anesthesiology And Acute Pain Medicine Meeting
2016-03-30,First Week of May 20th Options Trading For Trevena (TRVN)
2016-03-09,Trevena Reports Full Year 2015 Financial Results
2016-03-03,Trevena To Present At Three Upcoming Investor Events In March
2016-03-02,Trevena To Host Conference Call On March 9th To Discuss Full Year 2015 Financial Results
2016-02-26,Short Interest In Trevena Drops 16.4%
2016-02-22,Trevena Pain Drug Anointed 'Breakthrough Therapy' by FDA
2016-02-22,Trevena, Inc. Receives FDA Breakthrough Therapy Designation For Oliceridine For The Management Of Moderate-to-Severe Acute Pain
2016-02-17,Trevena To Present At The 2016 RBC Capital Markets' Global Healthcare Conference
2016-02-03,Trevena To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-20,Commit To Purchase Trevena At $5, Earn 22.1% Annualized Using Options
2016-01-19,Trevena, Inc. Announces Initiation Of Oliceridine Phase 3 Clinical Program With Multi-Procedure Safety And Tolerability Study
2016-01-11,Trevena Becomes Oversold (TRVN)
2015-12-16,Trevena, Inc. Added To NASDAQ Biotechnology Index (NBI)
2015-12-03,Trevena Announces FDA Grant Of Fast Track Designation To Oliceridine (TRV130) For The Management Of Moderate-to-Severe Acute Pain
2015-12-03,Trevena Granted Key Composition Of Matter And Use Patent For TRV027 In Europe
2015-12-02,Trevena To Present At The Oppenheimer 26th Annual Healthcare Conference
2015-12-01,Commit To Buy Trevena At $10, Earn 33.8% Annualized Using Options
2015-11-12,Trevena CEO To Present At The Jefferies 2015 Global Healthcare Conference
2015-11-10,Trevena Reports Third Quarter 2015 Financial Results And Provides Corporate Update
2015-10-28,Trevena Hosts Investor And Analyst Day
2015-10-23,5 Stocks Poised for Breakouts
2015-10-21,Trevena To Host Analyst And Investor Day On October 28, 2015
2015-10-16,Trevena: Friday's Small-Cap Focus Stock
2015-09-29,Trevena Announces Publication Of TRV130 Phase 2 Bunionectomy Data In The Journal PAIN®
2015-09-16,Trevena, Inc. Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-09-11,Trevena, Inc. Announces Pricing Of Underwritten Offering Of Common Stock
2015-09-10,Trevena, Inc. Announces Proposed Underwritten Offering Of Common Stock
2015-09-08,Trevena Announces Presentations At PAINWeek® 2015
2015-09-04,2 Issues Keeping Buyers on the Sidelines Today
2015-08-31,Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain
2015-08-11,Trevena Reports Second Quarter 2015 Financial Results And Provides A Corporate Update
2015-08-04,Trevena CEO To Present At The 2015 Wedbush PacGrow Healthcare Conference
2015-07-28,Short Interest Surges 277.7% For TRVN
2015-07-20,Trevena Appoints Yacoub Habib As Senior Vice President, Business Development And Corporate Planning
2015-06-29,Oversold Conditions For Trevena (TRVN)
2015-06-29,Trevena Added To Russell 3000®, Russell 2000®, And Russell Global Indexes
2015-06-18,Trevena Announces Poster Presentation Of Data For Delta Receptor Compound TRV250 At American Headache Society 57th Annual Scientific Meeting
2015-06-17,Trevena CEO To Present At The 2015 JMP Securities Life Sciences Conference
2015-06-02,Trevena Granted Key U.S. Composition Of Matter Patent For TRV734
2015-05-28,Trevena CEO To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-14,Trevena Announces Presentation Of Preclinical Data For Delta Receptor Compound TRV250 At International Headache Congress
2015-05-07,Trevena Reports First Quarter 2015 Financial Results And Provides A Corporate Update
2015-05-04,Trevena Appoints Carrie Bourdow As Chief Commercial Officer
2015-04-08,Trevena CEO To Present At The 14th Annual Needham Healthcare Conference
2015-03-18,Trevena CMO To Present At The BioCentury 22nd Annual Future Leaders In The Biotech Industry Conference
2015-03-18,Trevena Reports Full Year 2014 Financial Results
2015-03-11,Trevena To Host Conference Call On March 18th To Discuss Full Year 2014 Financial Results
2015-03-09,Trevena Completes Interim Analysis And Announces Plans For Ongoing Phase 2b BLAST-AHF Trial Of TRV027 In Acute Heart Failure
2015-03-06,5 Stocks Poised for Breakouts: Trevena, Inventergy and More
2015-03-04,Trevena CEO To Present At The Barclays Global Healthcare Conference
2015-02-24,Trevena CEO To Present At The Cowen And Company 35th Annual Health Care Conference
2015-02-23,Symic Biomedical Announces Appointment Of Barbara Yanni And Bill Newell As Independent Directors To Its Board
2015-02-09,Trevena Announces Positive Results From Phase 1 Multiple Ascending Dose Study Of TRV734 For Moderate To Severe Acute And Chronic Pain
2015-02-03,Trevena CEO To Present At The 17th Annual BIO CEO & Investor Conference
2015-02-03,TRV027 Phase 2b BLAST-AHF Trial Design Published In Journal Of The American College Of Cardiology: Heart Failure
2015-01-06,Trevena Initiates Second Phase 2b Study Of TRV130 For Acute Postoperative Pain
2014-12-17,Trevena Appoints Anne M. Phillips To The Board Of Directors
2014-12-10,Trevena Announces Closing Of Public Offering And Partial Exercise Of Underwriters' Option To Purchase Additional Shares
2014-12-04,Trevena Announces Pricing Of Public Offering
2014-12-01,Trevena Announces Commencement Of Public Offering
2014-11-17,Trevena Announces Positive Top-Line Results From Phase 2a/b Study Of TRV130 In Acute Postoperative Pain
2014-11-11,Trevena Reports Third Quarter 2014 Financial Results And Provides A Corporate Update
2014-10-13,RSI Alert: Trevena (TRVN) Now Oversold
2014-10-08,Trevena Announces Early Completion Of Enrollment Of Phase 2a/b Study Of TRV130 In Postoperative Pain
2014-09-22,Trevena Enters Into $35 Million Tranched Term Loan Credit Facility
2014-09-18,Trevena Appoints Adam M. Koppel To The Board Of Directors
2014-09-16,Trevena Granted Key U.S. Composition Of Matter Patent For TRV130
2014-08-13,4 Stocks Under $10 Making Big Moves
2014-08-12,Trevena Reports Second Quarter 2014 Financial Results
2014-08-07,Trevena CEO To Present At The Canaccord Genuity 34th Annual Growth Conference
2014-08-06,Trevena Initiates Phase 1 Multiple Ascending Dose Study Of TRV734 For Acute And Chronic Pain
2014-08-05,Trevena To Host Conference Call To Discuss Second Quarter 2014 Results On August 12
2014-08-05,Trevena Granted Key U.S. Method Of Use Patent For TRV027
,
